Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBER’s New Director “Marks” A New Era For Biologics Regulation

This article was originally published in RPM Report

Executive Summary

Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.

You may also be interested in...



FDA's Califf Seeks His First Big Hire: Chief Scientist

The US agency seeks candidates for the executive position in charge of its research policy apparatus.

FDA Chief Scientist Post A Chance For Califf To Make Mark

Agency seeks candidates for the executive position in charge of its research policy apparatus.

The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA

Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel